We recognized $110.0 million of other income during the year ended December 31, 2018, from the sale of our rare pediatric disease priority review voucher (PRV).

Amazing what competent management can accomplish. I imagine they also got a lot done along the way as far as setting targets and then doing what it takes to hit them.  Would have been nice if RVX had obtained a PRV as management had talked so confidently about a number of years ago.

To me the biggest reason RVX’s share price is where it is at currently is inept management. For a number of years they have basically stumbled around talking about a lot of objectives while realizing few if any self set targets. It is really a shame that at this point in time they don’t have partnerships for multiple trials on at least a few of the 7 or 8 other compounds which they have claimed, for a number of years, are clinic ready. Would have been nice to have a few strings to the bow at this time.